Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC

The goal of this study is to evaluate whether prophylactic endoscopic variceal ligation (EVL) can prevent esophageal variceal bleeding in patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev) therapy. The study will also assess the safety of prophylactic EVL in this population. The main question it aims to answer is: Does prophylactic EVL in high-risk varices reduce the incidence of variceal bleeding to a level similar to that of low-risk varices in HCC patients receiving Atezo/Bev? Participants will: 1. Undergo prophylactic EVL before starting Ate

Trial Details

NCT ID
NCT06819566
Phase
PHASE2
Sponsor
Asan Medical Center
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Endoscopic variceal ligation (EVL)
Locations (sample)
  • Seoul, Song-pa, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Patients aged 19 years or older and under 80 years.
  • Patients with liver function are classified as Child-Pugh Class A.
  • Barcelona Clinic Liver Cancer stage C patients with no prior systemic anticancer therapy for hepatocellular carcinoma.
  • Patients with an Eastern Cooperative Oncology Group performance score of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →